|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The immunostain scores were obtained as the degree of cytoplasmic FOXO1A intensity multiplied by the percentage of positively stained tumor area.
|
30664534 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that TFAP2B, ALK and a novel marker OLIG2 may serve as surrogate markers for PAX3/7-FOXO1 status what is especially beneficial in cases where poor quality tumour tissue is not suitable for reliable genetic analyses or shows inconclusive result.
|
31493794 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protective effects of FoxO1:S<sup>249</sup>V were detected by the xenograft tumor formation assay.
|
30453847 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with NC + Vector group, mimics + Vector group has higher OD495 value (<i>P</i> < 0.05), higher migration and invasion cells (<i>P</i> < 0.01), larger transplanted tumor volume (<i>P</i> < 0.01), lower FOXO1 positive cell numbers (<i>P</i> < 0.01), higher p-AKT and p-GSK-3β expression (<i>P</i> < 0.01), lower p-β-catenin expression (<i>P</i> < 0.01), more β-catenin expression in the nucleus (<i>P</i> < 0.01).
|
30828264 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-96 can be considered as one of tumor-inducer and form competing endogenous RNA network with FOXO1 and DUSP1, which affects downstream EGFR signaling.
|
31579447 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, FOXO1 inhibited cell proliferation and tumor formation both <i>in vitro</i> and <i>in vivo</i>, and promoted pancreatic cancer cell invasion.
|
31217876 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After the diagnosis, cfDNA was serially collected to detect the PAX3-FOXO1 fusion sequence as a tumor marker. cfDNA could be an appropriate source for detecting the fusion gene; assays using cfDNA have proved to be useful for the early detection of tumor progression/recurrence.
|
30739374 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, genes with PAX3-FOXO1 binding sites and promoter hypomethylation exhibited the highest frequency of overexpression in FP tumors.
|
30565669 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that Forkhead Box O1 (FOXO1) protein, a tumor suppressor, regulates expression of nicotinamide phosphoribosyltransferase (Nampt) in human breast cancer MCF-7 cells.
|
30799084 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our studies demonstrated that CB potently induced FOXO1-mediated DDP sensitivity by antagonizing its binding partner MYH9 to modulate tumor stemness in NPC.
|
31754475 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For example, the MYB-NFIB fusion in adenoid cystic carcinoma is regulated by IGF1R through an autocrine loop, and IGF1R is a downstream target of the EWSR1-WT1 and PAX3-FKHR fusions in desmoplastic small round cell tumors and alveolar rhabdomyosarcoma, respectively.
|
31426421 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the microarray analysis is utilized to preliminarily clarify the oncogenic molecular mechanisms regulated by NDC80 and the results suggest it may promote CRC progression partly by downregulating tumor suppressors such as dual specificity phosphatase 5 and Forkhead box O1.
|
29341479 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326).
|
30478420 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
|
30272279 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This article may serve as a guide for future research and identify FOXO1 as a potent therapeutic target in neoplasms.
|
29473160 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, AFU showed a sufficient inhibitory effect on the phosphorylation of FOXO1, a tumor suppressor, in monotherapy or in combination with PD, which may be attributable to the activation of FOXO1, the subsequent inhibition of tumor growth, and the induction of cell death.
|
29928335 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, a disruption of FOXO1 with CRISPR/Cas9 genome-editing (sgFOXO1) resulted in CD20 upregulation, improved the cytotoxicity induced by rituximab and the survival of mice with sgFOXO1 tumors.
|
29721381 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual luciferase assay indicated tumor suppressor FOXO1 was a direct target of miR-27a.
|
30138596 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRPM7 Regulates AKT/FOXO1-Dependent Tumor Growth and Is an Independent Prognostic Indicator in Renal Cell Carcinoma.
|
29545479 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Met-induced phosphorylation of FoxO1 initiates a reduction in the expression levels of G6Pase mRNA, which results in an overall increase in the uptake of [<sup>18</sup>F]FDG into HCC cells and tumors.
|
29256045 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we used FoxO1 conditional knockout mice to show that FoxO1 deficiency in myeloid cells exacerbates tumor growth.
|
29238041 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We previously reported a CAF case with monoallelic 13q14 deletion in which the tumor expressed decreased levels of FOXO1 and RB1, both of which were encoded in 13q14, and increased reactive oxygen species (ROS) levels.
|
28887603 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate PAX3-FOXO1 represses miR-221/222 that functions as a tumor suppressing microRNA through the negative regulation of CCND2, CDK6, and ERBB3.
|
29367756 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Forkhead box class O1 (FOXO1) acts as a tumor suppressor in solid tumors.
|
30333121 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As a cancer repressor, reviving the activity of Foxo1 forces tumor-infiltrating activated regulatory T (T<sub>reg</sub>) cells to egress from tumor tissues.
|
29309928 |
2018 |